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Abstract
Philadelphia-negative myeloproliferative neoplasms (MPNs) are a diverse group of diseases whose common feature is the
presence of V617F mutation of the JAK2 gene. In the era of novel therapeutic strategies in MPNs, such as JAK-inhibitor therapy,
there is a growing need for establishing high sensitive quantitative methods, which can be useful not only at diagnosis but also for
monitoring therapeutic outcomes, such as minimal residual disease (MRD). In this study, we compared the qPCR and ddPCR
methods and their clinical utility for diagnosis, prognostication, and treatment monitoring of MPNs with JAK2 V617F mutation
in 63 MPN patients of which 6 were subjected to ruxolitinib treatment. We show a high conformance between the two methods
(correlation coefficient r = 0.998 (p < 0.0001)). Our experiments revealed high analytical sensitivity for both tests, suggesting that
they are capable of detecting the JAK2V617F mutation at diagnosis of MPN with a limit of detection (LoD) of 0.12% for qPCR
and 0.01% for ddPCR. The alterations of JAK2 V617F allele burden in patients treated with ruxolitinib were measured by both
methods with equal accuracy. The results suggest an advantage of ddPCR in monitoring MRD because of allele burdens below
the LoD of qPCR. Overall, the clinical utility of qPCR and ddPCR is very high, and both methods could be recommended for the
routine detection of the V617F mutation at diagnosis, though ddPCR will probably supersede qPCR in the future due to cost-
effectiveness.
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Introduction
The JAK2 V617F mutation is present in a high proportion of
patients diagnosed with Philadelphia-negative myeloprolifer-
ative neoplasms (MPNs). Mutated V617F alleles are detected
in approximately 95% of patients diagnosed with
polycythemia vera (PV) and in approximately 60% of patients
diagnosed with primary myelofibrosis (PMF) and essential
thrombocythemia (ET) [1]. Mutations localized within the ex-
on 12 of the JAK2 gene are rare and described in 2–5% of PV
patients [2]. Detection of the JAK2 V617F mutation is part of
the diagnostic criteria of myeloid neoplasms in the recent
World Health Organization (WHO) classification [3].
Available data show that the burden of JAK2 V617F alleles
could correlate with the phenotypic presentation of MPN [4],
severity of the disease phenotype [5], the risk of thrombotic
events [6, 7], progression to post-PV myelofibrosis [8], and
survival [9]. Thus, quantification of the JAK2V617Fmutation
at diagnosis provides important prognostic information. In
addition, JAK2 V617F quantification is also very useful dur-
ing the course of treatment tomonitor response to therapy with
JAK2 inhibitors, alpha-interferon, or allogeneic stem-cell
transplantation (allo-HSCT) [10].
Two highly sensitive molecular techniques—quantitative
polymerase chain reaction (qPCR) and droplet digital PCR
(ddPCR)—are currently available for a quantitative evaluation
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of JAK2 V617F mutation allele burden in patients diagnosed
with MPNs. However, the amount of data regarding a direct
comparison of these methods used at diagnosis and for mini-
mal residual disease (MRD) monitoring in MPN patients is
limited.
Aims
The aim of this study was to compare the accuracy and clinical
utility of qPCR and ddPCR applied at diagnosis and in MRD
monitoring of JAK2 V617F-positive patients with myelopro-
liferative neoplasms.
Materials and methods
Patient samples
Peripheral blood samples were collected from 63 MPN pa-
tients at time of diagnosis at the Department of Hematology,
University Hospital in Kraków, Poland. The group consisted
of 20 patients suffering from PV, 20 patients with ET, and 23
patients with PMF. From six patients diagnosed with PMF
undergoing therapy with ruxolitinib (JAK2 inhibitor), an ad-
ditional blood sample was collected for MRD monitoring.
MPNs were diagnosed according to 2008WHO classification
criteria. All patients provided informed written consent, and
the study was approved by the local Ethics Committee.
Clinical and laboratory characteristics of patients are de-
scribed in Table 1.
Control samples
Two separate groups of control samples were used in the
study. For qPCR, blood samples were collected from 30
healthy individuals recruited from the Department of
Hematology, University Hospital in Kraków, Poland. For
ddPCR, samples from more than 600 normal donors were
analyzed, and in 192 samples, positive JAK2 V617F droplets
were detected. The samples were collected at Zealand
University Hospital in Roskilde/Naestved, Denmark.
Methods
DNA isolation
Blood samples were treated with NH4Cl lysis buffer before
isolation of nucleic acids. Genomic DNAwas extracted from
the leukocytes using the NucleoSpinTissue Columns
(MACHEREY-NAGEL GmbH & Co. KG, Düren,
Germany) according to the manufacturer’s instructions and
was quantified spectrophotometrically using a NanoDrop
Lite Spectrophotometer (Thermo Fisher Scientific,
Wilmington, USA).
Quantitative PCR (qPCR)
The qPCR was performed as described by Larsen et al. [11].
This assay was found to have the best performance profile and
was selected by ELN/MPN&MPNr-EuroNet as the optimal
qPCR assay for routine diagnosis and monitoring of MRD
in JAK2 V617F-positive MPN patients [12]. PCR was per-
formed using 25 ng DNA in a total volume of 25 μl (12.5 μl
TaqMan Universal PCR Master Mix (with UNG and ROX)
[Thermo Fisher Scientific, Waltham, MA USA], 2.5 μl 10×
primers/probe mix, 5 μl nuclease-free water, and 5 μl DNA
5 ng/μl). The primer concentration was 300 nmol/l and the
probe concentration was 200 nmol/l. The PCR protocol was
an initial enzyme activation step of 2 min at 50 °C and 10 min
at 95 °C, followed by 50 cycles of 95 °C for 15 s and 60 °C for
60 s. All qPCR reactions were performed in duplicates on the
Viia 7 Real-Time PCR System (Applied Biosystem, Foster
City, CA). The percentage of JAK2 V617F mutated alleles
were calculated as [copy-numberJAK2V617F/(copy-
Table 1 Clinical characteristics
of patients suffering from Ph-
negative MPNs at diagnosis. PV
polycythemia vera, ET essential
thrombocythemia, PMF primary
myelofibrosis
Characteristics PV ET PMF
Number of patients 20 20 23
Median age, years (range) 57.5 (20–85) 42.5 (20–82) 62 (35–78)
Gender, M/F 11/9 8/12 13/10
Median hemoglobin, g/dl (range) 16.9 (14–22.7) 13.9 (10.5–16.1) 11.6 (8.2–16)
Median hematocrit, % (range) 52 (40–67) 40.6 (34.1–46.4) 35.9 (28–51)
Median red blood cell, M/μl (range) 5.8 (3.9–7.8) 4.6 (3.5–5.7) 4.2 (2.7–5.9)
Median white blood cell, K/μl (range) 11.1 (4.1–70.2) 7.2 (4.7–19.5) 9.5 (5.2–22.5)
Median platelets, K/μl (range) 694.5 (59–2500) 397 (150–893) 530 (119–1200)
Splenomegaly, number of patients 7 (1 lack of result) 2 (1 lack of result) 12 (2 lack of results)
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numberJAK2V617F + copy-numberJAK2wild-type)] × 100. This
calculation was made with the use of qPCR standard curve
in which the absolute copy number of mutated allele and wild-
type allele of JAK2 in each standard sample was evaluated
previously by ddPCR. The standard curve was prepared fol-
lowing recommendations of MPN&MPNr-EuroNet consor-
tium as a result of quality control assurance of qPCR methods
for JAK2V617F evaluation.
Droplet digital PCR (ddPCR)
The Bio-Rad’s QX200 system (Bio-Rad Laboratory,
Hercules, California, USA) was used to perform ddPCR. In
each ddPCR reaction, two probes were used: a FAM-labeled
probe for the JAK2V617Fmutation and a HEX-labeled probe
for the JAK2 V617F wild-type allele. Usage of two probes in
one reaction allowed the simultaneous detection and calcula-
tion of both the mutant and the wild-type alleles. The reaction
volume was 20 μl (10 μl 2× ddPCR Supermix for Probes [no
dUTP], 2 μl 10× primers/probes mix, 3 μl nuclease-free water
with 5 μl of genomic DNA). The primer concentration was
300 nmol/l, and the probe concentration was 200 nmol/l. PCR
was performed in a Veriti PCR instrument (Thermo Fisher)
using the following conditions: 95 °C for 10 min, followed by
40 cycles of 94 °C for 30 s, and 57 °C for 60 s with a final
stage at 98 °C for 10 min. After thermal cycling, the 96-well
plate was read in the QX200 Droplet Reader, and based on
positive droplets and according to the Poisson distribution, the
absolute copy number of the JAK2 V617F and wild-type
JAK2 alleles was calculated using the QuantaSoft analysis
software (Bio-Rad Laboratory, Hercules, California, USA).
The percentage of JAK2 V617F mutated alleles were calcu-
lated as [copy-numberJAK2V617F/(copy-numberJAK2V617F +
copy-numberJAK2wild-type)] × 100. The samples were analyzed
in triplicates.
Evaluation of the limit of blank (LoB) and the limit
of detection (LoD)
Limit of blank (LoB) and limit of detection (LoD) were cal-
culated to avoid false positive and false negative results, and
reliably to measure and critically describe the minimum
amount of JAK2 V617F that could be detected in the context
of highly sensitive allele-specific assays.
Both parameters for qPCR and ddPCR platforms were in-
dependently tested and based on different groups of samples.
LoB and LoD for qPCR
For the qPCR method, the LoB was established by measuring
false positive events from a series of 30 wild-type control
samples. The calculation was based on the average value of
the measurements using the formula: LoB =mean blank +
1645 × SDblank, where SD is the standard deviation. By the
estimation of LoB, the lowest JAK2V617F allele burden with
95% confidence was set with clearly cut-off signals from the
background.
LoD was established by preparation of twofold dilution
series of genomic DNA derived from UKE-1 cell line (homo-
zygous JAK2 V617F mutation) re-suspended in wild-type
DNA, covering the range 0.0098–2.5000% of JAK2 V617F
per reaction volume. Each standard point was analyzed in 50
replicates. To identify the outliers, Grubb’s test was per-
formed, and finally, 444 data points were used for the analysis.
The received data were analyzed using GeneEx 6.1 (trial ver-
sion, MultiD analyses AB) under current MIQE (Minimum
Information for Publication of Quantitative Real-Time PCR
Experiments) [13] and CLSI (Clinical Laboratory Standards
Institute) guidelines [14] according to the protocol described
by Forootan et al. [15]. LoD gives the possibility to detect the
lowest percentage of JAK2 V617F allele burden in a sample
with 95% probability, ensuring ≤ 5% false positives, in the
used molecular method. Furthermore, the limit of detection
accurately expresses the analytical sensitivity of an assay [13].
LoB and LoD for ddPCR
The calculation of LoB was based on the average percentage
of JAK2 V617F mutated alleles measured in the 192 normal
donors samples, where JAK2 V617F-positive droplets were
detected. The LoD was calculated with the 99% confidence
from the formula: LoD = LoB + 3 × SD.
Statistical analysis
The GraphPad version 4.0 software (La Jolla, CA, USA) was
used to calculate the statistical parameters. A comparison be-
tween qPCR and ddPCR, on the basis of clinical samples, was
performed using the Spearman rank correlation coefficient
analysis. Bland-Altman analysis was used to evaluate the
agreement among the two PCR methods in clinical samples.
Subsequently, a comparison between allele burden medians
measured by both methods separately for different MPNs
was performed by the Mann-Whitney test. Additionally, six
patients were compared before and after 2–22 months of ther-
apy with ruxolitinib, and the quantitative variable was ana-
lyzed with the Student paired t test. A p value < 0.05 was
considered statistically significant.
Results
The calculation of LoB for qPCR defines background level
based on the 30 wild-type control samples and was equaled to
0.0086% of the V617F allele burden. For the ddPCR, the
calculation of LoB was determined to 0.0026%. Considering
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the assay performance, the established LoD defined the lowest
concentration of JAK2 V617F allele that could be detected
and was set at 0.12% for qPCR (95% confidence level), and
0.01% for ddPCR (99% confidence level) (Fig. 1). These data
showed one logarithm higher sensitivity of ddPCR compared
to qPCR.
The Spearman’s rho test showed a high conformance be-
tween the two methods with a correlation coefficient of r =
0.998, p < 0.0001 (Fig. 2). The test confirmed 100% positive
results overlap between the methods. Additionally, in a Bland-
Altman test, the bias between the measurements obtained by
qPCR vs ddPCR was evaluated. The bias was at the level of
2.3 and more than 95% (95.15%) of differences of measure-
ments lay within the limit of agreement (Fig. 3). Finally, the
medians of the JAK2 V617F quantification were comparable
between the two methods (Fig. 4).
Among the 63 patients diagnosed with MPNs, the JAK2
V617F mutation was detected using qPCR in 44 patients
(69.8%). The median allele burden was 33.2% (range 0.34–
92.8%). In ddPCR, 45 of 63 patients (71.4%) were positive for
JAK2 V617F mutation with a median allele burden of 36.5%
(range 0.011–93.7%). The mutation was identified in 85% of
patients with PV. The median allele burden was 37.2% (range
2.9–73.4) according to qPCR analysis. In ddPCR, the median
allele burden was 40.2% (range 3.5–74.2%). Additionally, in
both methods, four PV patients were characterized as homo-
zygous, 13 as heterozygous, and in 3 (15%) patients, the JAK2
V617F mutation was not detected (including mutations in
exon 12). The JAK2 V617F-negative patients with
RCPddRCPq
LoB
LoB = meanblank + 1,645(SDblank )
SD- the standard deviaon
LoB=0,0086% 
of the JAK2 V617F allele burden
LoB = meanFraconal Abundance/192
LoB= 0,0026% 
of the JAK2 V617F allele burden
LoD
LoD=0,12% 
with 95% probability, ensuring ≤5% false posives
LoD=0,01% 
with 99% probability, ensuring ≤1% false posives
LoD = LoB + 3 x SD
Fig. 1 Estimation of limit of detection (LoD) for qPCR and ddPCR
methods. For qPCR, fractions of positive reads were fitted to sigmoidal
curve and the LoD was estimated at 95% confidence level. For ddPCR,
LoD calculation was based on limit of blank (LoB) value and standard
deviation (SD) of measurements
Fig. 2 Correlation between qPCR and ddPCR (r = spearman correlation
coefficient)
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erythrocytosis was diagnosed with PV according to 2008
WHO classification criteria and after thorough analysis of
trephine biopsy. Among ET patients, 12 (60%) and 13
(65%) were tested JAK2 V617F mutation positive in qPCR
and ddPCR, respectively. The median allele burden was
16.5% (range 4.0–40.7%) by qPCR and 17.4% by ddPCR
(range 0.011–44.4%), respectively. One ET patient had a
low mutation burden of 0.011% measured by ddPCR. With
a corresponding mutation burden by qPCR calculated to be
below LoD: 0.02%, the JAK2 V617F positivity remains in-
conclusive in this patient. In the ET group, all positive patients
were heterozygous. The measurements in PMF patients
showed the presence of the mutation in 65.2% cases both by
qPCR and ddPCR. The median allele burden by qPCR was
37.5% (range 0.34–92.8%) and 42% (range 0.45–93.7%) by
ddPCR. Both methods confirmed the presence of homozygos-
ity in seven patients and heterozygosity in eight patients (re-
sults demonstrated in Fig. 5).
No statistical differences between qPCR and ddPCR in the
assessments of JAK2 V617F allele burden within all three
subgroups of MPNs were found (Fig. 4). Of note, despite no
statistical difference were revealed, ddPCR values were slight-
ly higher than qPCR in all but two cases (0.002% and 0.011%
for ddPCR and 0.010% and 0.02% for qPCR, respectively).
The allele burdens in the six PMF patients at diagnosis
compared with the allelic burden during ruxolitinib therapy
showed statistically significant differences when measured
with ddPCR, whereas this was seen in five patients measured
with qPCR. In four out of six patients, we observed a statisti-
cally significant reduction of the mutated allele burden during
ruxolitinib therapy (Table 2). According to the revised IWG-
MRT and ELN recommendations, patients 2–6 fulfilled
criteria for partial molecular remission assessment (≥ 12-week
time interval between allele burden measurements and a mu-
tant allele burden at baseline ≥ 20%). However, none of the
analyzed patients obtained a partial molecular remission (≥
50% decrease in allele burden). In two patients (no. 3 and no.
5), the allele burden increased during therapy (Table 2) which
corresponded to progressive splenomegaly and increased per-
centage of myeloblasts in peripheral blood suggesting the pro-
gression of the disease.
Discussion
The prognostic significance of the JAK2 V617F mutation,
including the allelic burden, has been investigated in many
studies [6, 7, 16, 17]. In our study, we compared two highly
sensitive molecular methods: the qPCR and ddPCR in relation
to detection and quantification of the JAK2V617Fmutation in
patients suffering from MPNs. We detected the JAK2 V617F
mutation to be present in about two-thirds of our ET and PMF
3876,0 = P6326,0 = P3535,0 = P
Fig. 4 Comparison of median JAK2 V617F allele burden measured by
qPCR and ddPCR. Mann-Whitney U test shows no significant
differences between the two methods. PV+: patients diagnosed with
polycythemia vera, ET+: patients diagnosed with essential
thrombocythemia, PMF+: patients diagnosed with primary myelofibrosis
Fig. 3 The differences between
measurements by qPCR and
ddPCR (y axis) vs. the mean of
the sample quantification
performed by qPCR and ddPCR
(x axis) (the Bland-Altman plot).
Dotted lines indicate bias (mean
difference) and 95% limits of
agreement (upper limit + 2 SD;
lower limit − 2 SD) between the
two given methods. A 95.12% of
presented measurements fitted to
the limit of agreement
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patients, which is in line with other reports [7, 9, 18–21]. The
percentage of JAK2 V617F mutation detected in our PV pa-
tient group was lower (85%) than is usually reported [5,
21–23], probably due to a limited number of samples ana-
lyzed. Homozygosity in PVand ET has been associated with
increased risk of fibrotic transformation [17, 24–27], lower
platelet count, higher incidence of splenomegaly, and larger
spleen size [16, 17]. Homozygous ET patients also have a
higher incidence of thrombotic events [24]. In accordance
with other studies [4, 26], our quantitative measurements of
V617F posive
V617F negave
V617 posive
V617F negave
V617F posive
V617F negave
PV ET PMF
n=20 n=20 n=23
85% %56)71(  %2.56)31(  (15)
15% (3)
35% (7) 34,8% (8)
Homozygous - 23% (4)
Range: 52.3-73.4% V617F qPCR
Range: 56.9-74.2% V617F ddPCR
Heterozygous - 77% (13)
Range: 2.9-44.9% V617F qPCR
Range: 3.5-47.5% V617F ddPCR
Homozygous - absent
Heterozygous - 100% (13)
Range: 4.0-40.7% V617F qPCR
Range: 0.011-44.4% V617F ddPCR
Homozygous - 47% (7)
Range: 53.3-92.8% V617F qPCR
Range: 56.7-93.7% V617F ddPCR
Heterozygous - 53% (8)
Range: 0.34-41.3% V617F qPCR
Range: 0.45-45.1% V617F ddPCR
Fig. 5 Distribution of JAK2 V617F-positive MPN patients and their
allele burden within subgroups on the basis of ddPCR results. Among
the patients diagnosed with ET, the JAK2 V617F mutation was detected
in 12 patients (60%) with qPCR and in 13 patients (65%) with ddPCR.
One patient had a low mutation burden of 0.011% measured by ddPCR
with a corresponding mutation burden of 0.02% measured in qPCR (this
value was calculated below qPCR LoD)
Table 2 V617F mutant allele load analyses in patients with PMF treated with JAK2 inhibitor (ruxolitinib)
% JAK2V617F Nominal
allele burden
change
p value
(*p < 0.05)
Relative
allele
burden
change
% JAK2V617F Nominal
allele burden
change
p value
(*p < 0.05)
Relative
allele
burden
change
Before
JAK2
inhibitor
therapy
During
JAK2
inhibitor
therapy
Before
JAK2
inhibitor
therapy
During
JAK2
inhibitor
therapy
1 2 0.61 0.03 − 0.58 0.0296* 95.1% 0.75 0.069 − 0.68 0.0025* 90.8%
2 22 55.45 42.92 − 12.53 0.0071* 22.6% 56.66 42.62 − 14.04 0.001* 24.8%
3 19 66.60 75.67 + 9.07 0.0184* 13.6% 66.5 77.39 + 10.89 0.0196* 16.4%
4 3 29.96 20.53 − 9.43 0.0106* 31.5% 36.46 21.47 − 14.99 0.0026* 41.1%
5 3 73.41 74.68 + 1.27 0.665 1.7% 75.42 78.15 + 2.73 0.0151* 3.6%
6 3 65.12 60.14 − 4.98 0.0016* 7.6% 68.98 62.32 − 6.66 0.0007* 9.6%
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PVand PMF patients revealed a higher median JAK2 V617F
allele burden compared to ET patients. Homozygosity in ET
patients only occurs rarely in up to 2–4% of cases [6, 16], and
accordingly, none of our ET samples showed a mutational
load higher than 50% (Fig. 5). These results show a concor-
dance between the level of allele burden and severity of MPN
disease in that PVand PMF have a poorer overall survival than
ET [28]. In contrast, a low allele burden within PMF patients
has been associated with more severe disease resulting in a
reduced overall survival, which is probably due to a cytopenic
phenotype rather than a myeloproliferative one [7].
Additionally, it has been suggested that a level of mutation
≥ 50% in PMF predicts a better response to JAK2 inhibitor
therapy [29]. In addition to be this Bgenetic risk factor^ for
prognosis, JAK2 V617F allele burden may also be used as a
MRD tool. According to the Italian Society of Hematology,
high-sensitivity quantitative assays are recommended for
monitoring MRD in all PMF patients after allogenic stem cell
transplantation (allo-SCT) [10] in order to identify patients at
higher risk of relapse [30] with the need of preemptive donor
lymphocyte infusion immunotherapy [31].
In our study, both qPCR and ddPCR showed consistent and
statistically important differences in the level of mutation be-
fore and during therapy with ruxolitinib in six patients.
However, due to relatively short-term follow-up, no prognos-
tic conclusion could yet be drawn. International Working
Group-Myeloproliferative Neoplasms Research and
Treatment (IWG-MRT) and the European LeukemiaNet re-
cently proposed molecular remission as one of the response
criteria of myelofibrosis therapy, which emphasizes the impor-
tance of accurate and sensitive methods in the era of novel and
more effective therapies in PMF. It has been proposed that
when screening for JAK2 V617F mutation, the qPCR should
be the method of choice due to a greater reproducibility and
sensitivity compared to qualitative methods, and for molecular
monitoring of MRD after allo-SCT, ddPCR would be a pre-
ferred option [10]. In the latter case, the ability to detect mu-
tated clones even with low allele burden (mutation loads <
1%) allows to predict relapse [12]. According to Watherhouse
et al., JAK2 V617F mutation was detected with higher fre-
quency by ddPCR than qPCR. Digital PCR allows good per-
formance by achieving absolute quantification, thereby
minimalizing the difficulties of result interpretation when test
results are below the limit of quantification and over the limit
of detection [32].
In patients suffering from MPNs, the positivity thresh-
old for quantitative detection of JAK2 V617F mutation at
diagnosis should be at least 1–3% of allele burden [33–35].
In our study, both qPCR and ddPCR demonstrated high
sensitivity, enabling to detect the mutant allele burden at
diagnosis, also below 1%. The information regarding the
size of the mutated clone at diagnosis could be very im-
por tant , s ince even low al le le burden could be
pathologically relevant and clinically significant. The im-
plementation of ddPCR in the diagnostics of MPN could
result in detection of MPN at early stage. The preliminary
results, obtained on 20,000 healthy Danish people, consid-
er the low allele burden less than 1% as correlating with
mild leukocytosis. This in future perspective may result in
reduction of thrombotic and hemorrhagic events in pa-
tients, due to earlier diagnosis of pre-MPN and introduc-
tion of proper treatment [36]. The measurement of the low
JAK2 V617F allele burden could offer the new prognostic
parameter, which presumably could be applied for thera-
peutic interventions. Another aspect of using ddPCR meth-
od with higher LoD in detection of JAK2 V617F mutation
is the association with clonal hematopoiesis of indetermi-
nate potential (CHIP). The presence of genetic abnormali-
ties in genes related to the development of myeloid neo-
plasms in aging population (e.g., JAK2, DNMT3, TET2,
and ASXL1) [37] is associated with increased risk of hema-
tologic malignancies, all-cause mortality, and cardiovascu-
lar disease [37, 38]. In these cases, the evaluation of low
JAK2 V617F allele burdens in the healthy individuals in
contribution with other CHIP mutations could serve as an
important marker for early detection of clinical progression
to disease in at-risk individuals [39, 40]. Furthermore,
ddPCR could detect low allele burdens as a sign of the
presence of a small mutated clone within an overall poly-
clonal hematopoiesis [41], which may arise independently
[41, 42] and finally lead to myeloproliferative disease.
Therefore, monitoring of low JAK2 V617F allele burden
by ddPCR over time with clinical observation could be-
come an important strategy. Furthermore, in these cases,
further screening for the coexistence of mutation occurring
either in JAK2 exon 12, in MPL or in CALR gene is rec-
ommended [41, 43, 44]. In our study, in all three patients
with low JAK2 V617F allele burden (< 1%) detected by
qPCR and ddPCR, additional analyses showed a complex
mutational pattern with coexistence of mutations in the
ASXL1, CALR, and MPL gene, respectively (data not
shown). However, the detection of small clones around
and below 1% should be considered in the context of other
clinical parameters, since the V617F mutation of JAK2
gene has been detected at low levels in other disorders than
MPNs as well as in healthy individuals, and its clinical
significance is still not established [33–35]. Therefore, in
our study, a non-specific background below the LoB for
qPCR and ddPCR methods was estimated based on healthy
controls. Furthermore, the threshold for false positive
events was estimated independently for qPCR and
ddPCR which allowed to classify wild-type samples as
negative by both methods.
The high quality of the qPCR assay used within this study
for JAK2 V617F quantification was confirmed during quality
control assurance conducted by MPN&MPNr-EuroNet
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consortium. A corresponding international quality control and
an assay standardization have not yet been established for
ddPCR. Therefore, the application of ddPCR in diagnostic
and treatment evaluation has been based on clinical and meth-
odological experiences developed in-house. Clinical-
diagnostic assays require high-throughput protocol with accu-
rately fixed analytical parameters such as LoD. Our experi-
ments revealed high analytical sensitivity and specificity for
both tests, suggesting that they could serve as reliable diag-
nostic tools to detect the JAK2 V617F mutation in the diag-
nosis of MPN. Our comparison of qPCR and ddPCR suggests
that the two methods could be used interchangeably for diag-
nostic purposes and MRD monitoring, provided that the clin-
ically acceptable discrepancy between the results falls within
the designated agreement interval. Although the bias between
the methods is relatively small, its clinical relevance should
be, however, taken into account in patients with low allele
burdens, such as during evaluation of treatment response
and/or relapse after allo-SCT. In some rare cases, however,
none of the assays can guarantee 100% accurate quantification
of mutation alleles. The co-existence of additional mutation
within the primer or probe-annealing site can potentially re-
duce or prevent the amplification of the investigated sequence
[34].
It should be emphasized that ddPCR is characterized by
higher precision and sensitivity in assessment of a low con-
centration of the JAK2V617F mutation, which is important in
terms of measuring the actual biological and clinical mutation
status [31]. Therefore, ddPCR seems to be particularly suit-
able for precise monitoring of MRD. Last but not least, the
ddPCR method is more cost-effective than qPCR since it is a
multiplex reaction in contrast to two independent qPCR reac-
tions with the need for running additional standard curves.
Our findings suggest that ddPCR could be a complementary
approach for MRD monitoring in MPN patients and that
ddPCR probably will supersede qPCR in the future.
Acknowledgments We would like to thank the entire team of the
Molecular Diagnostics Laboratory of the Department of Hematology
Diagnostics at the University Hospital in Krakow. We would like to
acknowledge Tina Rasmussen for technical assistance and Małgorzata
Rucińska for clinical data collection.
Compliance with ethical standards
Conflict of interest The authors declare that they have no conflict of
interest.
Ethical approval All procedures performed in studies involving human
participants were in accordance with the ethical standards of the institu-
tional and/or national research committee and with the 1964 Helsinki
declaration and its later amendments or comparable ethical standards.
Informed consent Informed consent was obtained from all individual
participants included in the study.
Open Access This article is distributed under the terms of the Creative
Commons At t r ibut ion 4 .0 In te rna t ional License (h t tp : / /
creativecommons.org/licenses/by/4.0/), which permits unrestricted use,
distribution, and reproduction in any medium, provided you give appro-
priate credit to the original author(s) and the source, provide a link to the
Creative Commons license, and indicate if changes were made.
References
1. Cross NC (2011) Genetic and epigenetic complexity in myelopro-
liferative neoplasms. Hematol Am Soc Hematol Educ Program
2011:208–214. https://doi.org/10.1182/asheducation-2011.1.208
2. Scott LM, Tong W, Levine RL, Scott MA, Beer PA, Stratton MR,
Futreal PA, Erber WN, McMullin MF, Harrison CN, Warren AJ,
Gilliland DG, Lodish HF, Green AR JAK2 exon 12 mutations in
polycythemia vera and idiopathic erythrocytosis. N Engl J Med
356(5):459–68
3. Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau
MM, Bloomfield CD, Cazzola M, Vardiman JW (2016) The 2016
revision to the World Health Organization classification of myeloid
neoplasms and acute leukemia. Blood 127(20):2391–2405
4. Larsen TS, Pallisgaard N, Møller MB, Hasselbalch HC (2007) The
JAK2 V617F allele burden in essential thrombocythemia, polycy-
themia vera and primary myelofibrosis—impact on disease pheno-
type. Eur J Haematol 79(6):508–515
5. Vannucchi AM, Antonioli E, Guglielmelli P, Pardanani A, Tefferi A
(2008) Clinical correlates of JAK2V617F presence or allele burden
in myeloproliferative neoplasms: a critical reappraisal. Leukemia
22(7):1299–1307
6. Vannucchi AM, Antonioli E, Guglielmelli P, Rambaldi A, Barosi
G, Marchioli R, Marfisi RM, Finazzi G, Guerini V, Fabris F, Randi
ML, De Stefano V, Caberlon S, Tafuri A, Ruggeri M, Specchia G,
Liso V, Rossi E, Pogliani E, Gugliotta L, Bosi A, Barbui T (2007)
Clinical profile of homozygous JAK2 617V>F mutation in patients
with polycythemia vera or essential thrombocythemia. Blood
110(3):840–846
7. Guglielmelli P, Barosi G, Specchia G, Rambaldi A, Lo Coco F,
Antonioli E, Pieri L, Pancrazzi A, Ponziani V, Delaini F, Longo
G, Ammatuna E, Liso V, Bosi A, Barbui T, Vannucchi AM
(2009) Identification of patients with poorer survival in primary
myelofibrosis based on the burden of JAK2V617F mutated allele.
Blood 114(8):1477–1483
8. Koren-Michowitz M, Landman J, Cohen Y, Rahimi-Levene N,
Salomon O, Michael M, Amariglio N, Nagler A (2012)
JAK2V617F allele burden is associated with transformation to my-
elofibrosis. Leuk Lymphoma 53(11):2210–2213
9. Tefferi A, Lasho TL, Huang J, Finke C, Mesa RA, Li CY, Wu W,
Hanson CA, Pardanani A (2008) Low JAK2V617F allele burden in
primary myelofibrosis, compared to either a higher allele burden or
unmutated status, is associated with inferior overall and leukemia-
free survival. Leukemia 22(4):756–761
10. Guglielmelli P, Pietra D, Pane F, Pancrazzi A, Cazzola M,
Vannucchi AM, Tura S, Barosi G (2017) Recommendations for
molecular testing in classical Ph1-neg myeloproliferative disor-
ders—a consensus project of the Italian Society of Hematology.
Leuk Res 58:63–72
11. Larsen TS, Christensen JH, Hasselbalch HC, Pallisgaard N (2007)
The JAK2 V617F mutation involves B- and T-lymphocyte lineages
in a subgroup of patients with Philadelphia-chromosome negative
chronic myeloproliferative disorders. Br J Haematol 136(5):745–
751
2306 Ann Hematol (2018) 97:2299–2308
12. Jovanovic JV, Ivey A, Vannucchi AM, Lippert E, Oppliger
Leibundgut E, Cassinat B, Pallisgaard N, Maroc N, Hermouet S,
Nickless G, Guglielmelli P, van der Reijden BA, Jansen JH,
Alpermann T, Schnittger S, Bench A, Tobal K, Wilkins B, Cuthill
K, McLornan D, Yeoman K, Akiki S, Bryon J, Jeffries S, Jones A,
Percy MJ, Schwemmers S, Gruender A, Kelley TW, Reading S,
Pancrazzi A, McMullin MF, Pahl HL, Cross NC, Harrison CN,
Prchal JT, Chomienne C, Kiladjian JJ, Barbui T, Grimwade D
(2013) Establishing optimal quantitative-polymerase chain reaction
assays for routine diagnosis and tracking of minimal residual dis-
ease in JAK2-V617F-associated myeloproliferative neoplasms: a
joint European LeukemiaNet/MPN&MPNr-EuroNet (COSTaction
BM0902) study. Leukemia 27(10):2032–2039
13. Bustin SA, Benes V, Garson JA, Hellemans J, Huggett J, Kubista
M, Mueller R, Nolan T, Pfaffl MW, Shipley GL, Vandesompele J,
Wittwer CT (2009) The MIQE guidelines: minimum information
for publication of quantitative real-time PCR experiments. Clin
Chem 55(4):611–622
14. Tholen DW, Linnet K, Kondratovich M, Armbruster DA, Garrett
PE, Jones RL, Kroll MH, Lequin RM, Pankratz TJ, Scassellati GA,
Schimmel H, Tsai J (2004) NCCLS. Protocols for determination of
limits of detection and limits of quantitation; approved guideline.
NCCLS document EP17-a. NCCLS, Pennsylvania
15. Forootan A, Sjöback R, Björkman J, Sjögreen B, Linz L, KubistaM
(2017) Methods to determine limit of detection and limit of quan-
tification in quantitative real-time PCR (qPCR). Biomol Detect
Quantif 12:1–6
16. Vannucchi AM, Pieri L, Guglielmelli P (2011) JAK2 allele burden
in the myeloproliferative neoplasms: effects on phenotype, progno-
sis and change with treatment. Ther Adv Hematol 2(1):21–32
17. Tefferi A, Lasho TL, Schwager SM, Strand JS, Elliott M, Mesa R,
Li CY, Wadleigh M, Lee SJ, Gilliland DG (2006) The clinical
phenotype of wild-type, heterozygous, and homozygous
JAK2(V617F) in polycythemia vera. Cancer 106(3):631–635
18. Tefferi A (2010) Novel mutations and their functional and clinical
relevance in myeloproliferative neoplasms: JAK2, MPL, TET2,
ASXL1, CBL, IDH and IKZF1. Leukemia 24(6):1128–1138
19. Knoops L, Hermans C, Ferrant A, Constantinescu SN (2008)
Clinical implications of JAK2 mutations in myeloproliferative dis-
orders. Acta Clin Belg 63(2):93–98
20. Rumi E, Elena C, Passamonti F (2010) Mutational status of mye-
loproliferative neoplasms. Crit Rev Eukaryot Gene Expr 20(1):61–
76
21. Barbui T, Thiele J, Gisslinger H, Kvasnicka HM, Vannucchi AM,
Guglielmelli P, Orazi A, Tefferi A (2018) The 2016 WHO classifi-
cation and diagnostic criteria for myeloproliferative neoplasms:
document summary and in-depth discussion. Blood Cancer J 8(2):
15
22. Tefferi A, Lasho TL, Schwager SM, Strand JS, Elliott M, Mesa R,
Li CY, Wadleigh M, Lee SJ, Gilliland DG (2006) The clinical
phenotype of wild-type, heterozygous, and homozygous
JAK2V617F in polycythemia vera. Cancer 106(3):631–635
23. Levine RL, Belisle C, Wadleigh M, Zahrieh D, Lee S, Chagnon P,
Gilliland DG, Busque L (2006) X-inactivation-based clonality anal-
ysis and quantitative JAK2V617F assessment reveal a strong asso-
ciation between clonality and JAK2V617F in PV but not ET/
MMM, and identifies a subset of JAK2V617F-negative ET and
MMM patients with clonal hematopoiesis. Blood 107(10):4139–
4141
24. Antonioli E, Guglielmelli P, Poli G, Bogani C, Pancrazzi A, Longo
G, Ponziani V, Tozzi L, Pieri L, Santini V, Bosi A, Vannucchi AM
(2008) Influence of JAK2V617F allele burden on phenotype in
essential thrombocythemia. Myeloproliferative disorders research
consortium (MPD-RC). Haematologica 93(1):41–48
25. Tefferi A, Lasho TL, Schwager SM, Steensma DP, Mesa RA, Li
CY, Wadleigh M, Gary Gilliland D (2005) The JAK2(V617F)
tyrosine kinase mutation in myelofibrosis with myeloid metaplasia:
lineage specificity and clinical correlates. Br J Haematol 131:320–
328
26. Passamonti F, Rumi E, Pietra D, Della Porta MG, Boveri E,
Pascutto C, Vanelli L, Arcaini L, Burcheri S, Malcovati L,
Lazzarino M, Cazzola M (2006) Relation between JAK2 (V617F)
mutation status, granulocyte activation, and constitutive mobiliza-
tion of CD34+ cells into peripheral blood in myeloproliferative
disorders. Blood 107:3676–3682
27. Sangle N, Cook J, Perkins S, Teman CJ, Bahler D, Hickman K,
Wilson A, Prchal J, Salama ME (2014) Myelofibrotic transforma-
tions of polycythemia vera and essential thrombocythemia are mor-
phologically, biologically, and prognostically indistinguishable
from primary myelofibrosis. Appl Immunohistochem Mol
Morphol 22(9):663–668
28. Tefferi A, Guglielmelli P, Larson DR, Finke C, Wassie EA, Pieri L,
Gangat N, Fjerza R, Belachew AA, Lasho TL, Ketterling RP,
Hanson CA, Rambaldi A, Finazzi G, Thiele J, Barbui T,
Pardanani A, Vannucchi AM (2014) Long-term survival and blast
t r ans fo rma t ion in mo lecu l a r ly anno ta t ed essen t i a l
thrombocythemia, polycythemia vera, and myelofibrosis. Blood
124(16):2507–2513
29. Barosi G, Klersy C, Villani L, Bonetti E, Catarsi P, Poletto V,
Campanelli R, Impera S, Latagliata R, Viarengo G, Carolei A,
Massa M, Musso M, Crescimanno A, Gale RP, Rosti V (2016)
JAK2(V617F) allele burden ⩾50% is associated with response to
ruxolitinib in persons with MPN-associated myelofibrosis and
splenomegaly requiring therapy. Leukemia 30(8):1772–1775
30. Lange T, Edelmann A, Siebolts U, Krahl R, Nehring C, Jäkel N,
Cross M, Maier J, Niederwieser D, Wickenhauser C (2013) JAK2
p.V617F allele burden in myeloproliferative neoplasms one month
after allogeneic stem cell transplantation significantly predicts out-
come and risk of relapse. Haematologica 98(5):722–728
31. Kröger N, AlchalbyH,Klyuchnikov E, BadbaranA,Hildebrandt Y,
Ayuk F, Bacher U, Bock O, Kvasnicka M, Fehse B, Zander A
(2009) JAK2-V617F–triggered preemptive and salvage adoptive
immunotherapy with donor-lymphocyte infusion in patients with
myelofibrosis after allogeneic stem cell transplantation. Blood
113:1866–1868
32. WaterhouseM, FolloM, Pfeifer D, von Bubnoff N, Duyster J, Bertz
H, Finke J (2016) Sensitive and accurate quantification of JAK2
V617F mutation in chronic myeloproliferative neoplasms by drop-
let digital PCR. Ann Hematol 95(5):739–744
33. Bench AJ, White HE, Foroni L, Godfrey AL, Gerrard G, Akiki S,
Awan A, Carter I, Goday-Fernandez A, Langabeer SE, Clench T,
Clark J, Evans PA, Grimwade D, Schuh A, McMullin MF, Green
AR, Harrison CN, Cross NC (2013) Molecular diagnosis of the
myeloproliferative neoplasms: UK guidelines for the detection of
JAK2 V617F and other relevant mutations British Committee for
Standards in Haematology. Br J Haematol 160(1):25–34
34. Lippert E, Mansier O, Migeon M, Denys B, Nilsson A, Rosmond
C, Lodé L, Ugo V, Lascaux A, Bellosillo B, Martinez-Lopez J,
Naguib D, Gachard N, Maroc N, Hermouet S (2014) Clinical and
biological characterization of patients with low (0.1-2%)
JAK2V617F allele burden at diagnosis. Haematologica 99(7):
e98–101
35. Sidon P, El Housni H, Dessars B, Heimann P (2006) The
JAK2V617F mutation is detectable at very low level in peripheral
blood of healthy donors. Leukemia 20(9):1622
36. Cordua S, Kjaer L, Skov V, Ellervik C, Pallisgaard N, Hasselbalch
HC (2018) unexpected prevalences of the JAK2V617F and CALR
mutations in the general population. Abstract, EHA Learning
Center 214616
37. Jaiswal S, Fontanillas P, Flannick J, Manning A, Grauman PV, Mar
BG, Lindsley RC, Mermel CH, Burtt N, Chavez A, Higgins JM,
Moltchanov V, Kuo FC, Kluk MJ, Henderson B, Kinnunen L,
Ann Hematol (2018) 97:2299–2308 2307
Koistinen HA, Ladenvall C, Getz G, Correa A, Banahan BF,
Gabriel S, Kathiresan S, Stringham HM, McCarthy MI, Boehnke
M, Tuomilehto J, Haiman C, Groop L, Atzmon G, Wilson JG,
Neuberg D, Altshuler D, Ebert BL. Age-related clonal hematopoi-
esis associated with adverse outcomes. N Engl J Med 371(26):
2488–98
38. Genovese G, Kähler AK, Handsaker RE, Lindberg J, Rose SA,
Bakhoum SF, Chambert K, Mick E, Neale BM, Fromer M,
Purcell SM, Svantesson O, Landén M, Höglund M, Lehmann S,
Gabriel SB, Moran JL, Lander ES, Sullivan PF, Sklar P, Grönberg
H, Hultman CM, McCarroll SA. Clonal hematopoiesis and blood-
cancer risk inferred from blood DNA sequence. N Engl J Med
371(26):2477–87
39. Zink F, Stacey SN, Norddahl GL, Frigge ML, Magnusson OT,
Jonsdottir I, Thorgeirsson TE, Sigurdsson A, Gudjonsson SA,
Gudmundsson J, Jonasson JG, Tryggvadottir L, Jonsson T,
Helgason A, Gylfason A, Sulem P, Rafnar T, Thorsteinsdottir U,
Gudbjartsson DF, Masson G, Kong A, Stefansson K. Clonal hema-
topoiesis, with and without candidate driver mutations, is common
in the elderly. Blood 130(6):742–752
40. Nancy K. Padron G. Padron E. Chipping in on clonal hematopoie-
sis. Oncotarget 8(49): 84637–84638
41. Perricone M, Polverelli N, Martinelli G, Catani L, Ottaviani E,
Zuffa E, Franchini E, Dizdari A, Forte D, Sabattini E, Cavo M,
Vianelli N, Palandri F. The relevance of a low JAK2V617F allele
burden in clinical practice: a monocentric study. Oncotarget 8(23):
37239–37249
42. Beer PA, Jones AV, Bench AJ, Goday-Fernandez A, Boyd
EM, Vaghela KJ, Erber WN, Odeh B, Wright C, McMullin
MF, Cullis J, Huntly BJ, Harrison CN, Cross NC, Green AR
(2009) Clonal diversity in the myeloproliferative neoplasms:
independent origins of genetically distinct clones. Br J
Haematol 144(6):904–908
43. Tefferi A, Lasho TL, Finke CM, Knudson RA, Ketterling R,
Hanson CH, Maffioli M, Caramazza D, Passamonti F, Pardanani
A (2014) CALR vs JAK2 vs MPL-mutated or triple-negative my-
elofibrosis: clinical, cytogenetic and molecular comparisons.
Leukemia 28(7):1472–1477
44. Usseglio F, Beaufils N, Calleja A, Raynaud S, Gabert J
(2017) Detection of CALR and MPL mutations in low alle-
lic burden JAK2 V617F essential thrombocythemia. J Mol
Diagn 19(1):92–98
2308 Ann Hematol (2018) 97:2299–2308
